Zhenyuan Dong
Overview
Explore the profile of Zhenyuan Dong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szymura S, Wang L, Zhang T, Cha S, Song J, Dong Z, et al.
Nat Commun
. 2024 Aug;
15(1):6874.
PMID: 39128904
Lymphoplasmacytic lymphoma (LPL) is an incurable low-grade lymphoma with no standard therapy. Nine asymptomatic patients treated with a first-in-human, neoantigen DNA vaccine experienced no dose limiting toxicities (primary endpoint, NCT01209871)....
2.
Kwak L, Szymura S, Wang L, Zhang T, Cha S, Dong Z, et al.
Res Sq
. 2023 Oct;
PMID: 37790486
Lymphoplasmacytic lymphoma (LPL) is an incurable low-grade B-cell lymphoma of the bone marrow. Despite a cumulative risk of progression, there is no approved therapy for patients in the asymptomatic phase....
3.
Wang Z, Zhang T, Anderson A, Lee V, Szymura S, Dong Z, et al.
Biomedicines
. 2023 Mar;
11(3).
PMID: 36979775
Peripheral mononuclear blood cells (PBMCs) are the most widely used study materials for immunomonitoring and antigen-specific T-cell identification. However, limited patient PBMCs and low-frequency antigen-specific T cells remain as significant...
4.
Dong J, Dong Z, Feng P, Gao Y, Li J, Wang Y, et al.
Vaccines (Basel)
. 2023 Feb;
11(2).
PMID: 36851268
Live attenuated influenza vaccines offer broader and longer-lasting protection in comparison to inactivated influenza vaccines. The neuraminidase (NA) surface glycoprotein of influenza A virus is essential for the release and...
5.
Dong Z, Song J, Thieme E, Anderson A, Oh E, Cheng W, et al.
Blood Adv
. 2022 Dec;
7(6):918-932.
PMID: 36469551
B-cell activating factor receptor (BAFF-R) is a mature B-cell survival receptor, which is highly expressed in a wide variety of B-cell malignancies but with minimal expression in immature B cells....
6.
Shen X, Dong Z, Sim C, Li Y
Polymers (Basel)
. 2022 Sep;
14(17).
PMID: 36080594
Self-healing materials, especially self-healing polyurea/polyurethane, to replace traditional coating has been of increasing interest in the past decade. The frequency of regular maintenance work can also be reduced as the...
7.
Wang X, Dong Z, Awuah D, Chang W, Cheng W, Vyas V, et al.
Leukemia
. 2022 Jan;
36(4):1015-1024.
PMID: 35039637
Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent antitumor effects in B-cell malignancies including acute lymphoblastic leukemia (ALL), but antigen loss remains the major cause of treatment failure....
8.
Dong Z, Cheng W, Smith D, Huang B, Zhang T, Chang W, et al.
Cancer Immunol Immunother
. 2020 May;
69(10):2139-2145.
PMID: 32451682
B-cell malignancies can potentially be cured by CD19 chimeric antigen receptor (CAR) T-cell therapy. Although clinical response rates can be up to 93% in acute lymphoblastic leukemia, treatment-related antigen loss...
9.
Qin H, Dong Z, Wang X, Cheng W, Wen F, Xue W, et al.
Sci Transl Med
. 2019 Sep;
11(511).
PMID: 31554741
CAR T cells targeting CD19 provide promising options for treatment of B cell malignancies. However, tumor relapse from antigen loss can limit efficacy. We developed humanized, second-generation CAR T cells...
10.
Liu Y, Wei G, Cheng W, Dong Z, Sun H, Lee V, et al.
Cancer Immunol Immunother
. 2018 Jun;
67(8):1181-1195.
PMID: 29855694
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with an immune suppressive phenotype. They represent a critical component of the immune suppressive niche described in cancer,...